<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600327</url>
  </required_header>
  <id_info>
    <org_study_id>S2209</org_study_id>
    <nct_id>NCT00600327</nct_id>
  </id_info>
  <brief_title>Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™</brief_title>
  <acronym>CABERNET</acronym>
  <official_title>Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety of the NexStent for&#xD;
      treatment of carotid artery lesions undergoing stenting with adjunctive use of the FilterWire&#xD;
      distal embolic protection device. The rates will be compared to an Objective Performance&#xD;
      Criterion (OPC) derived from historic data from high-risk patients undergoing surgical&#xD;
      intervention with Carotid endarterectomy. Patients included in this study are those at higher&#xD;
      risk for complications associated with CEA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major clinical events at one-year defined as any death, stroke or myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>30-day event rate defined as any death, stroke or myocardial infarction less than or equal to 30-days post-procedure; plus the 31-day to 12-month event rate defined as any ipsilateral stroke including any death as a result of an ipsilateral stroke.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NexStent™ technical success</measure>
    <time_frame>post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FilterWire EZ™ technical success</measure>
    <time_frame>post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall system technical success</measure>
    <time_frame>post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic success</measure>
    <time_frame>post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>24 hours post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Transient Ischemic Attack</condition>
  <condition>Thromboembolic Stroke</condition>
  <condition>Stroke Prevention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoTex™ NexStent™</intervention_name>
    <description>EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Filter Wire EZ™</intervention_name>
    <description>EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient is greater than or equal to 18 years of age.&#xD;
&#xD;
          -  Anticipated patient life expectancy is of at least one year from the date of the index&#xD;
             procedure.&#xD;
&#xD;
          -  Lesion is located in the common carotid artery (CCA) and/or the internal carotid&#xD;
             artery (ICA) or the carotid bifurcation.&#xD;
&#xD;
          -  Target vessel is the only vessel being treated at this intervention and the lesion is&#xD;
             less than or equal to 30 mm and can be treated with a single stent.&#xD;
&#xD;
          -  Vessel to be treated is between 4.0 mm and 9.0 mm in diameter.&#xD;
&#xD;
          -  Patient can be either symptomatic or asymptomatic; Symptomatic: Stenosis must be&#xD;
             greater than or equal to 50% as determined by angiogram and the patient has a history&#xD;
             of stroke, TIA and/or amaurosis fugax in the hemisphere supplied by the target vessel&#xD;
             within 180 days of the procedure.&#xD;
&#xD;
          -  Patient can be either symptomatic or asymptomatic; Asymptomatic: Stenosis must be&#xD;
             greater than or equal to 60% as determined by angiogram without any neurological&#xD;
             symptoms.&#xD;
&#xD;
          -  Distal vessel &quot;landing zone&quot; for placement of the FilterWire must be between 3.5 mm&#xD;
             and 5.5 mm in diameter with visual angiographic recommendations as described in the&#xD;
             IFU.&#xD;
&#xD;
          -  Female patients with no childbearing potential or a documented negative pregnancy test&#xD;
             (urine or blood) within 10 days of the index procedure.&#xD;
&#xD;
          -  Patient (or their legal guardian) understands the nature of the procedure and has&#xD;
             provided a signed informed consent using a form that has been reviewed and approved by&#xD;
             the Investigational Review Board/Ethics Committee of the respective clinical site&#xD;
             prior to the procedure. This will be obtained prior to participation in the study.&#xD;
&#xD;
          -  Patient is willing to comply with the protocol requirements and return to the&#xD;
             treatment center for all required clinical evaluations&#xD;
&#xD;
          -  Patient must fulfill at least one of the following Class I: Unstable angina, LVEF less&#xD;
             than 30%, CHF class III or class IV, dialysis dependent renal failure, severe COPD,&#xD;
             requirement for staged CABG or valve replacement post carotid index procedure,Previous&#xD;
             carotid endarterectomy with significant restenosis, total occlusion of the&#xD;
             contralateral carotid artery, Previous radiation treatment to the neck or radical neck&#xD;
             dissection, Target lesion is at or above the second vertebral body C2 or below the&#xD;
             clavicle, Inability to extend the head due to cervical arthritis or other cervical&#xD;
             disorders, Tracheostomy or tracheal stoma,Presence of laryngeal nerve palsy, Bilateral&#xD;
             carotid artery stenosis as determined by angiography.&#xD;
&#xD;
          -  If a patient does not meet Class I criteria, a patient must meet two of the follwing&#xD;
             class II criteria: Patient is greater than or equal to 75 years of age, Myocardial&#xD;
             infarction within previous 6 weeks, Requires staged peripheral vascular surgery (i.e.&#xD;
             abdominal aortic aneurysm repair) or other major surgery post carotid index procedure,&#xD;
             Two or more proximal or major diseased coronary arteries with greater than or equal to&#xD;
             70% stenosis that have not or cannot be revascularized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously placed stent in target vessel.&#xD;
&#xD;
          -  Total occlusion of target vessel (ICA or CCA).&#xD;
&#xD;
          -  Angiographically visible thrombus.&#xD;
&#xD;
          -  Carotid string sign (a tiny, long segment of contrast in the true lumen of the artery,&#xD;
             aneurysmal pouch formation, and the distal location of the arteriopathy) with poor&#xD;
             visualization of the distal vessel.&#xD;
&#xD;
          -  Vertebrobasilar insufficiency symptoms only, without clearly identifiable symptoms&#xD;
             referable to the targeted carotid artery.&#xD;
&#xD;
          -  Vessel anatomy precluding use of stent system or distal protection system.&#xD;
&#xD;
          -  Presence of carotid artery dissection.&#xD;
&#xD;
          -  Requirement for staged CABG, valve replacement or abdominal aortic aneurysm procedure&#xD;
             30 days before or after the index procedure.&#xD;
&#xD;
          -  Evidence of a major disabling stroke within the previous 30 days.&#xD;
&#xD;
          -  Patient has an evolving stroke or has experienced a major stroke (NIHSS score greater&#xD;
             than or equal to 15) within 3 months.&#xD;
&#xD;
          -  History of intracranial hemorrhage within the past 12 months.&#xD;
&#xD;
          -  Any condition that precludes proper angiographic assessment or makes percutaneous&#xD;
             arterial access unsafe, e.g. morbid obesity, history of chronic hypertension that is&#xD;
             not controlled by medical therapy.&#xD;
&#xD;
          -  Contraindication to heparin, aspirin, clopidogrel (Plavix®), X-ray contrast or&#xD;
             ticlopidine (Ticlid®)in cases of intolerance to clopidogrel.&#xD;
&#xD;
          -  History of liver failure with elevated prothrombin time.&#xD;
&#xD;
          -  History or current indication of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Hgb &lt;8 gm/dl (unless on dialysis), platelet count &lt; 50,000, WBC &gt;15,000, INR &gt; l.5&#xD;
             (irreversible) or heparin-associated thrombocytopenia.&#xD;
&#xD;
          -  Known cardiac sources of emboli not under treatment with anticoagulant therapy.&#xD;
&#xD;
          -  Atherosclerotic disease involving adjoining vessels precluding safe placement of the&#xD;
             guiding catheter or sheath.&#xD;
&#xD;
          -  Planned treatment of non-target lesion within 30 days.&#xD;
&#xD;
          -  Other abnormal angiographic findings that indicate the patient is at risk of a stroke&#xD;
             due to a problem other that the target lesion, such as: ipsilateral arterial stenosis&#xD;
             greater in severity than the target lesion, cerebral aneurysm, or arteriovenous&#xD;
             malformation (AVM) of the cerebral vasculature.&#xD;
&#xD;
          -  Dementia or confusion.&#xD;
&#xD;
          -  The patient is enrolled in another study protocol.&#xD;
&#xD;
          -  Patient may not participate in another investigational trial up to 12 months&#xD;
             post-index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl Fontana, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L. Nelson Hopkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Millard Filmore/Gates Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Subbarao Myla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoag Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oschner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millard Fillmore Gates Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia - Weill Cornell Division of Vascular Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh (UPMC-Shadyside)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Favaloro Institute</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1093</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Bethanien, Germany</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sieburg Heart Center, Germany</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>January 14, 2008</last_update_submitted>
  <last_update_submitted_qc>January 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cheryl Fontana</name_title>
    <organization>Boston Scientific</organization>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>thrombosis</keyword>
  <keyword>thromboembolic</keyword>
  <keyword>Transient Ischemic Attack</keyword>
  <keyword>TIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

